Ex-Claims Court Chief Chides Warren's Drug Pricing Plan
By Dani Kass (May 20, 2022, 9:28 PM EDT) -- Sen. Elizabeth Warren's suggestion for how to lower prescription drug costs by using branded companies' patents without permission doesn't hold up to legal scrutiny, according to former U.S. Court of Federal Claims Chief Judge Susan G. Braden.
Warren, D-Mass., in April called for using Section 1498(a) of the U.S. Code to let generic companies or the government make patent-protected drugs without the patent owner's permission, so long as they're properly compensated. But the former chief judge — in an article co-authored with Joshua A. Kresh, her current colleague at George Mason University's Center for Intellectual Property X Innovation Policy — said it's not...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!